Jia Li, Luo Shihua, Ren Xiang, Li Yang, Hu Jialei, Liu Bing, Zhao Lifen, Shan Yujia, Zhou Huimin
College of Laboratory Medicine, Dalian Medical University, Dalian, 116044, Liaoning Province, China.
Department of Traumatology, Shanghai Ruijin Hospital, Jiaotong University, Shanghai, 200025, China.
Dig Dis Sci. 2017 Dec;62(12):3447-3459. doi: 10.1007/s10620-017-4755-z. Epub 2017 Oct 13.
Metastasis is a leading cause of cancer-related death including colorectal cancer (CRC). MicroRNAs are known to regulate cancer pathways and to be expressed aberrantly in cancer. Aberrant sialylation is closely associated with malignant phenotype of tumor cells, including invasiveness and metastasis.
This study aimed to investigate the association of miR-182 and miR-135b with proliferation and invasion by targeting sialyltransferase ST6GALNAC2 in CRC cells and explore the potential molecular mechanism.
We measured the levels of miR-182, miR-135b, and ST6GALNAC2 in a series of CRC cell lines and tissues using real-time PCR. Bioinformatics analysis and luciferase reporter assay were performed to test the direct binding of miR-182 and miR-135b to the target gene ST6GALNAC2. We also analyzed the possible role of miR-182/-135b on colony formation, wound healing, invasion, and tube formation.
The expression of miR-182 and miR-135b was higher in tumor tissues compared to adjacent noncancerous tissues of CRC patients, as well as up-regulated in SW620 cells than in SW480 cells with different metastatic potential. By applying bioinformatics analysis and luciferase reporter assay, we identified ST6GALNAC2 as the direct target of miR-182/-135b. Furthermore, miR-182/-135b inhibited significantly ST6GALNAC2 expression, and consistently, ST6GALNAC2 mediated migration, adhesion, invasion, proliferation, and tumor angiogenesis in CRC cell lines. Additionally, PI3K/AKT signaling pathway was regulated by miR-182/135b, which was partially blocked by altered level of ST6GALNAC2 in CRC.
The miR-182/-135b/ST6GALNAC2/PI3K/AKT axis may serve as a predictive biomarker and a potential therapeutic target in CRC treatment.
转移是包括结直肠癌(CRC)在内的癌症相关死亡的主要原因。已知微小RNA可调节癌症通路并在癌症中异常表达。异常的唾液酸化与肿瘤细胞的恶性表型密切相关,包括侵袭和转移。
本研究旨在通过靶向唾液酸转移酶ST6GALNAC2,研究miR-182和miR-135b与CRC细胞增殖和侵袭的关联,并探索潜在的分子机制。
我们使用实时PCR测量了一系列CRC细胞系和组织中miR-182、miR-135b和ST6GALNAC2的水平。进行生物信息学分析和荧光素酶报告基因检测以测试miR-182和miR-135b与靶基因ST6GALNAC2的直接结合。我们还分析了miR-182/-135b对集落形成、伤口愈合、侵袭和管腔形成的可能作用。
与CRC患者的相邻非癌组织相比,肿瘤组织中miR-182和miR-135b的表达更高,并且在具有不同转移潜能的SW620细胞中比SW480细胞中上调。通过应用生物信息学分析和荧光素酶报告基因检测,我们确定ST6GALNAC2是miR-182/-135b的直接靶标。此外,miR-182/-135b显著抑制ST6GALNAC2表达,并且一致地,ST6GALNAC2介导CRC细胞系中的迁移、粘附、侵袭、增殖和肿瘤血管生成。此外,PI3K/AKT信号通路受miR-182/135b调节,这在CRC中被ST6GALNAC2水平的改变部分阻断。
miR-182/-135b/ST6GALNAC2/PI3K/AKT轴可能作为CRC治疗中的预测生物标志物和潜在治疗靶点。